store at low temperature
store at -20°C
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 147.00 | |
5 mg | In stock | $ 447.00 | |
10 mg | In stock | $ 713.00 |
Description | Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer. |
In vitro | Emibetuzumab (LY2875358) inhibits HGF-stimulated proliferation of H596 at a concentration of 100 nmol/L for 6 days[1]. |
In vivo | Emibetuzumab (LY2875358) exhibits antitumor effects on MET-amplified xenograft mouse tumor models. It inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice at a dose of 10 mg/kg via intravenous administration once a week for 5 weeks. Additionally, a single intravenous dose of 10 or 20 mg/kg results in the downregulation of MET and pMET levels in the tumors of mice. The antitumor effects persist when administered once a week for 3, 5, or 6 weeks at a dose of 10 mg/kg[1]. |
Synonyms | LY2875358 |
Molecular Weight | N/A |
CAS No. | 1365287-97-3 |
store at low temperature
store at -20°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Emibetuzumab 1365287-97-3 Tyrosine Kinase/Adaptors c-Met/HGFR LY 2875358 LY-2875358 LY2875358 inhibitor inhibit